KRAS and nasopharyngeal carcinoma: However, compared with that in lung cancer, the efficacy of TKIs is limited because of the low mutation rates of EGFR and KRAS in NPC patients, which is one of the main barriers hampering the development of targeted therapies for the disease [93,96,97].